Text Size

Combining Behavioral Treatment With Agonist Maintenance - 1

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2008 by National Institute on Drug Abuse (NIDA).
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Yale University
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000311
First received: September 20, 1999
Last updated: October 27, 2008
Last verified: October 2008
History of Changes
  Purpose

The purpose of this study is to evaluate whether the community reinforcement approach (CRA) plus contingency management (CM) is more effective overall than CRA only in reducing illicit opioid and cocaine use during agonist maintenance treatment and at 3 and 6 month follow-up after completion of study protocol, and to compare the efficacy of maintenance on buprenorphine to methadone when maintenance is combined with CRA only or CRA plus CM.


Condition Intervention Phase
Cocaine-Related Disorders
Opioid-Related Disorders
Substance-Related Disorders
 Drug: Buprenorphine
 Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Combining Behavioral Treatment With Agonist Maintenance

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Depression
  • Withdrawal symptoms
  • Opioid and cocaine use
  • Social and psychological functioning
  • AIDS risk behavior

Estimated Enrollment: 168
Study Start Date: September 1999
Arms Assigned Interventions
Experimental: 1
Therapeutic Contracting (TC)
 Drug: Buprenorphine
  1. Experimental Therapeutic Contracting (TC)
  2. Experimental Cognitive Behavioral Coping Skills Therapy (CBT)
Experimental: 2
Cognitive Behavioral Coping Skills Therapy (CBT)
 Drug: Buprenorphine
  1. Experimental Therapeutic Contracting (TC)
  2. Experimental Cognitive Behavioral Coping Skills Therapy (CBT)

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000311

Locations
United States, Connecticut
APT Residential Services Division
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Yale University
Investigators
Principal Investigator: Richard Schottenfeld, M.D. Yale University
  More Information

No publications provided

Responsible Party: Richard S. Schottenfeld, MD, Yale University School of Medicine
ClinicalTrials.gov Identifier: NCT00000311     History of Changes
Other Study ID Numbers: NIDA-09413-1, R01-09413-1
Study First Received: September 20, 1999
Last Updated: October 27, 2008
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Opioid-Related Disorders
Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Buprenorphine
Analgesics, Opioid
Analgesics
Sensory System Agents
 Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Central Nervous System Depressants
Narcotic Antagonists
Narcotics

ClinicalTrials.gov processed this record on May 21, 2013